Previous 10 | Next 10 |
2024-01-23 08:24:49 ET Rail Vision ( RVSN ) +29% . TKO Group Holdings ( TKO ) +19% . vTv Therapeutics ( VTVT ) +18% . Bit Brother ( BETS ) +13% . Jeffs Brands ( JFBR ) +10% . Rumble ( RUM )...
2024-01-17 20:15:07 ET Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has en...
2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...
2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...
2023-11-28 07:29:17 ET More on Pyxis Oncology Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed Seeking Alpha’s Quant Rating on Pyxis Oncology For further details see: Pyxis Oncology announces appointment of Kobayashi as CMO
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer (CMO), effecti...
PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg ; data expected 1H 2024. PYX-106 (a fully human immunotherapy antibody candidate): Phase 1 tri...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Pyxis Oncology Inc. (PYXS) is expected to report $-0.57 for Q3 2023
2023-10-13 09:00:17 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 13, 2023 – USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer ...
News, Short Squeeze, Breakout and More Instantly...
Pyxis Oncology Inc. Company Name:
PYXS Stock Symbol:
NASDAQ Market:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation ther...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
Pyxis Oncology, Inc. (NASDAQ: PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This ...